Expert Council resolution: adjunctive pharmacotherapy for hyperkinetic disorders (attention deficit hyperactivity disorder) in children and adolescents
O.L. Lapochkin, V.P. Zykov, N.N. Zavadenko, A.V. Goryunov, L.S. Chutko, A.N. Barhatova, E.V. Koren, T.A. Kupriyanova, A.P. Skoromets, S.V. Grechany, Yu.E. Nesterovsky, A.V. Goryunova, I.B. Komarova, M.V. Barkhatov, A.V. Sulimov, Zh.M. Tsotsonava, I.V. MakarovOn July 16, 2026, the Expert Council of the National Association of Pediatric Neurologists convened in Moscow in a hybrid format. The Council reviewed adjunctive pharmacotherapy for hyperkinetic disorders (F90 according to ICD-10; Attention-deficit hyperactivity disorders, ADHD; 6A05 according to ICD-11) in children and adolescents, focusing on evidence and clinical experience with medications used In Russian practice beyond the international first-line standard. Using the 2019 CECCMP evidence evaluation system and the current procedure for developing clinical guidelines linked to ICD-10 categories in the Russian Federation, the Council stratified medications into two groups. Group A, with the strongest evidence base (double-blind randomized controlled trial with a primary endpoint achieved in ADHD), includes Prospekta. Group B, with a limited evidence base, includes Cortexin, Tenoten for children, Cerebrolysin, Semax, Cogitum, Magne B6, Pantoham, and Mexidol. Adjunctive pharmacotherapy is recommended only as part of a multidisciplinary approach that includes psychoeducation and behavioral interventions. It is not a substitute for atomoxetine therapy for eligible patients.